Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular …

Aims Glucose-lowering, glucagon-like peptide-1 (GLP-1) receptor agonists reduce
incidence of major cardiovascular (CV) events in patients with Type 2 diabetes mellitus …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …

Objective. Data from randomized clinical trials with metabolic outcomes can be used to
address concerns about potential issues of cardiovascular safety for newer drugs for type 2 …

Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐
1RAs) in people with type 2 diabetes. Materials and methods We electronically searched, up …

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important
therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment's …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Several new glucose-lowering medications have been approved, such as dipeptidyl
peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium …

Aim Glucagon‐like peptide 1 receptor agonists (GLP1‐RA) reduce atherosclerotic events in
patients with type 2 diabetes (T2D) and a high cardiovascular risk. The effect of GLP1‐RA to …

Aims New drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due
regulatory requirements from the Food and Drug Administration. For this reason, glucagon …